The purpose of this clinical trial is to assess the effectiveness of ARIKAYCE, inhaled once daily, in patient populations with mild and untreated MAC lung infection.
Eligible patients include those who currently have a positive MAC sputum culture and have not received treatment for their infection.
The purpose of this clinical trial is to assess the effectiveness of Epetraborole, taken once daily, in patient populations with treatment-refractory MAC lung disease.
Eligible patients include those who currently have a positive MAC sputum culture despite receiving a combination regimen of at least 2 antimycobacterial agents administered for at least 6 months.